Stellungnahme der DGVS zur Nutzenbewertung von Bulevirtid (Chronische Hepatitis-Delta-Virus(HDV)-Infektion, HDV-RNA-positiv)

• Literatur

• 1 Zhang Z, Urban S. New Insights into Hepatitis D Virus Persistence: the Role of Interferon Response and Implications for Upcoming Novel Therapies. Journal of Hepatology 2020;
• 2 Romeo R. et al. A 28-Year Study of the Course of Hepatitis Δ Infection: A Risk Factor for Cirrhosis and Hepatocellular Carcinoma. Gastroenterology 2009; 136: 1629-1638
• 3 Wedemeyer H. et al. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. Lancet Infect Dis 2019; 19: 275-286
• 4 Heidrich B. et al. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology 2014; 60: 87-97
• 5 Lampertico P. et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. Journal of Hepatology 2017; 67: 370-398
• 6 Blank A. et al. First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. J Hepatol 2016; 65: 483-489
• 7 Yurdaydin C. et al. Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. J Hepatol 2019; 70: 1008-1015